A practical reference on TB-500: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-22. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
21 June – Harry Watson, artist and poet (born 1965). 24 June – Garry Ahern, sports broadcaster (Radio New Zealand) (born 1949). 26 June Takutai Tarsh Kemp, politician, MP for Tāmaki Makaurau (since 2023) (born 1975) Robbie Stuart, rugby union player (Hawke's Bay, national team) and coach (Hawke's Bay) (born 1948).
Akinesia A loss or impairment of voluntary movement, often associated with Parkinson's disease and basal ganglia dysfunction. Allodynia A condition in which normally non-painful stimuli are perceived as painful, often due to nerve damage or sensitization. Alpha wave A type of brainwave oscillation in the frequency range of 8–13 Hz, commonly associated with relaxed, wakeful states and measured using electroencephalography (EEG). Alzheimer's disease A progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and the presence of amyloid plaques and neurofibrillary tangles in the brain. Amygdala A brain structure involved in emotion, particularly fear, aggression, and emotional memory formation. It is part of the limbic system. Anencephaly A severe congenital condition in which a major portion of the brain, skull, and scalp is missing due to failed closure of the neural tube. Anhedonia The inability to experience pleasure, commonly associated with depression and certain neurological disorders. Anterograde amnesia A form of memory loss in which new memories cannot be formed following brain injury or trauma; often associated with damage to the hippocampus. Anterior cingulate cortex A region of the cingulate cortex implicated in functions such as emotion regulation, cognitive control, error detection, and decision-making. Aphasia A language disorder resulting from brain damage, most often in the left hemisphere, that affects the production or comprehension of speech and writing.
=== First modular space station === The USSR turned its space program to the development of the low Earth orbit modular space station Mir (peace or world) assembled in orbit from 1986 to 1996. At 129,700 kilograms (285,900 lb), it held records for the largest spacecraft and the longest continuous human presence in space at 3,644 days, until the International Space Station was built starting in 1998. Mir's operation continued after the 1991 replacement of the USSR's space program with the Russian Federal Space Agency until 2001, supported by Soyuz spacecraft.
Sources: en.wikipedia.org
Lamont Bentley (October 25, 1973 – January 19, 2005) was an American actor and rapper best known for his role as Hakeem Campbell on the UPN sitcom Moesha. Bentley was also known for his role as Crazy K in the 1995 horror film Tales from the Hood and C-Money in the 2001 film The Wash featuring Dr. Dre and Snoop Dogg.
=== Osmotic drying using a humectant === Osmotic dehydration is the process of soaking food in highly concentrated solutions of humectant. Salt and sugar are commonly used humectants for this process. Water diffusion from the food to the humectant solution is caused by osmotic pressure. The water is replaced by the humectant, which results in a lowered water activity for the food product. Osmotic dehydration process results in two way mass transfer in regards to the moisture lost and the solids gained, with moisture loss being much greater than the addition of solids. Advantages of osmotic dehydration include low processing temperatures, short drying times, and 20-30% lower energy consumption than typical dehydration processes. Sugar is used as the humectant for candied intermediate moisture fruits, and salt is used for intermediate moisture vegetables and fish. Additionally, a mixture of humectants can be formulated to manipulate the sensory properties of the food product. Osmotic drying using a humectant results in a soft texture in the final product.
===== MeSH D08.811.682.657 – oxidoreductases acting on aldehyde or oxo group donors ===== MeSH D08.811.682.657.163 – aldehyde oxidoreductases MeSH D08.811.682.657.163.249 – aldehyde dehydrogenase MeSH D08.811.682.657.163.249.750 – omega-crystallins MeSH D08.811.682.657.163.311 – aldehyde oxidase MeSH D08.811.682.657.163.342 – aminomuconate-semialdehyde dehydrogenase MeSH D08.811.682.657.163.374 – aspartate-semialdehyde dehydrogenase MeSH D08.811.682.657.163.468 – benzaldehyde dehydrogenase (NADP+) MeSH D08.811.682.657.163.515 – betaine-aldehyde dehydrogenase MeSH D08.811.682.657.163.562 – glutamate-5-semialdehyde dehydrogenase MeSH D08.811.682.657.163.750 – glyceraldehyde-3-phosphate dehydrogenases MeSH D08.811.682.657.163.750.250 – glyceraldehyde 3-phosphate dehydrogenase (nadp+) MeSH D08.811.682.657.163.750.300 – glyceraldehyde-3-phosphate dehydrogenase (nadp+)(phosphorylating) MeSH D08.811.682.657.163.750.350 – glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) MeSH D08.811.682.657.163.781 – glycolaldehyde dehydrogenase MeSH D08.811.682.657.163.796 – l-aminoadipate-semialdehyde dehydrogenase MeSH D08.811.682.657.163.812 – malonate-semialdehyde dehydrogenase (acetylating) MeSH D08.811.682.657.163.827 – methylmalonate-semialdehyde dehydrogenase (acylating) MeSH D08.811.682.657.163.835 – retinal dehydrogenase MeSH D08.811.682.657.163.843 – succinate-semialdehyde dehydrogenase MeSH D08.811.682.657.163.875 – succinate-semialdehyde dehydrogenase (NAD(P)+) MeSH D08.811.682.657.180 – formate dehydrogenases MeSH D08.811.682.657.350 – ketone oxidoreductases MeSH D08.811.682.657.350.750 – ketoglutarate dehydrogenase complex MeSH D08.811.682.657.350.750.500 – dihydrolipoamide dehydrogenase MeSH D08.811.682.657.350.760 – 3-methyl-2-oxobutanoate dehydrogenase (lipoamide) MeSH D08.811.682.657.350.825 – 2-oxoisovalerate dehydrogenase (acylating) MeSH D08.811.682.657.350.875 – pyruvate dehydrogenase (lipoamide) MeSH D08.811.682.657.350.937 – pyruvate oxidase MeSH D08.811.682.657.350.968 – pyruvate synthase
Sources: en.wikipedia.org
== Ongoing challenges and future directions == Despite the advances in technology and theory, lichen systematics faces several challenges as it moves forward, ranging from practical issues of workforce and resources to conceptual debates about how we define and name species.
Blastula-stage cells can behave as pluripotent stem cells in many species. Pluripotent stem cells are the starting point to produce organ specific cells that can potentially aid in repair and prevention of injury and degeneration. Combining the expression of transcription factors and locational positioning of the blastula cells can lead to the development of induced functional organs and tissues. Pluripotent Xenopus cells, when used in an in vivo strategy, were able to form into functional retinas. By transplanting them to the eye field on the neural plate, and by inducing several mis-expressions of transcription factors, the cells were committed to the retinal lineage and could guide vision based behavior in the Xenopus. Polarity in embryogenesis Diploblasty Triploblasty
== Uranium-230 == Uranium-230 is an artificial isotope of uranium with a half-life of 20.8 days. It has potential to be used in targeted alpha therapy. It is prepared from decay of protactinium-230, which is produced from proton irradiation of thorium targets.
=== A10BB Sulfonylureas === A10BB01 Glibenclamide A10BB02 Chlorpropamide A10BB03 Tolbutamide A10BB04 Glibornuride A10BB05 Tolazamide A10BB06 Carbutamide A10BB07 Glipizide A10BB08 Gliquidone A10BB09 Gliclazide A10BB10 Metahexamide A10BB11 Glisoxepide A10BB12 Glimepiride A10BB31 Acetohexamide
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.